Immuneering (IMRX) Revenue (2020 - 2022)

Immuneering's Revenue history runs 3 years deep, the most recent figure standing at $455.0 for Q4 2022.

• In Q4 2022, Revenue fell 99.76% year-over-year to $455.0; the TTM figure through Sep 2023 stood at $455.0 (down 99.91% YoY), while the FY2022 annual figure was $316952.0, down 84.76% from the prior year.
• Revenue for Q4 2022 stood at $455.0, down from $38380.0 in the prior quarter.
• The five-year high for Revenue was $748200.0 in Q1 2021, with the low at $455.0 in Q4 2022.
• The 3-year median for Revenue is $480835.0 (2020), against an average of $384127.1.
• The sharpest annual moves came in 2021 and 2022: Revenue soared 37.27% in 2021, then tumbled 99.76% in 2022.
• Immuneering's Revenue stood at $665080.0 in 2020, then tumbled by 71.49% to $189591.0 in 2021, then sank by 99.76% to $455.0 in 2022.
• Business Quant data shows IMRX's Revenue at $455.0 in Q4 2022, $38380.0 in Q3 2022, and $94419.0 in Q2 2022.